Oral Dextrose Gel in the Treatment of Neonatal Hypoglycemia: An Evidence Based Practice Change

593-Thumbnail Image.png
Description

Background: Neonatal hypoglycemia (NH) is a common problem in the newborn period that resolves by 24-48 hours of life. Infants with known NH risk factors take longer to achieve blood glucose homeostasis. The leading cause of neonatal intensive care unit

Background: Neonatal hypoglycemia (NH) is a common problem in the newborn period that resolves by 24-48 hours of life. Infants with known NH risk factors take longer to achieve blood glucose homeostasis. The leading cause of neonatal intensive care unit (NICU) admissions in otherwise healthy term and late preterm infants is NH.

Purpose: To determine the efficacy of dextrose gel in addition to oral feedings in NH treatment as compared to the previous practice of oral feedings alone. Lewin's change theory was used in staff education and project implementation.

Methods/Search Strategy: A keyword search of CINHAL, Cochrane, and PubMed with restrictions to English and publications within 5 years revealed supportive data for the practice change. IRB approval obtained prior to the practice change. Nurses screened all newborns for NH risk factors at birth at a tertiary hospital in the southwestern U.S. Infants with specific criteria received oral dextrose gel with timed follow-up blood glucose levels following an NH algorithm.

Findings/Results: Two groups of infants with similar gestational ages, birth weights, and risk factors for NH were compared pre and post-implementation of the EBP change. Infants in the first group (n=27) were all born prior to the start of the project and therefore were all treated with IV dextrose in the NICU after failing to maintain blood glucose levels within normal ranges with oral feedings alone. The second group of infants (n=27) was treated based on an updated NH algorithm after implementation of the use of oral dextrose gel. Of those 27 infants, 24 received oral dextrose gel for NH treatment. Of respiratory distress in addition to NH so these infants were excluded in the statistical analysis of NICU admissions. Therefore the post-implementation group only had 2 admission for primary diagnosis of NH. When comparing admission rates for hypoglycemia between the two groups, the first group had a 100% admission rate while the second group (those who received oral dextrose gel) only had a 9% admission rate for neonatal hypoglycemia (p<0.001). Upon further investigation it was found that these 2 infants admitted to the NICU with the diagnosis of NH had multiple risk factors present, including being infants of diabetic mothers which means they likely experienced refractory hypoglycemia after treatment with oral dextrose gel secondary to hyperinsulinism. Hyperinsulinism can lead to persistent and profound hypoglycemia in the newborn that is more difficult to treat, which is of clinical significance.

Implications for Practice: Early identification with timely follow-up blood glucose levels following intervention may be critical to successful treatment without requiring NICU admission. Nursing education and parental support are also paramount to success. If the change in NICU admissions for NH is statistically significant with a larger sample size, results may be shared with other facilities that traditionally transfer these infants for a higher level of care.

Implications for Research: Studies with larger sample size may generate more generalizable data with fewer outliers. Studies comparing neurodevelopmental outcomes among infants who received different NH treatments are necessary to determine long-term safety.

Date Created
2018-05-09
Agent